AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12133040 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 402
Study 10451130 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg suppositories
Number of subjects: 57
Study 10451130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 7783014 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant overdentures with O-ring attachments
Number of subjects: 17
Study 7783014 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant overdentures with magnet attachments
Number of subjects: 17
Study 7783014 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 17
Study 7783014 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant overdentures
Number of subjects: 17
Study 2191111 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metronidazole (three 400 mg tablets daily for 1 week)
Number of subjects: 98
Study 2191111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 147633 — intervention group
Group type: COMPARATOR
Intervention: Portacaval shunting
Number of subjects: 24
Study 147633 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesocaval shunting
Number of subjects: 24
Study 31422216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 361
Study 31422216 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice (IC) of single-agent chemotherapy (methotrexate, docetaxel, or cetuximab)
Number of subjects: 361
Study 31422216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 361
Study 27977513 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pressure massage applied to the shoulders and neck
Number of subjects: 17
Study 27977513 — intervention group
Group type: COMPARATOR
Intervention: Quiet sitting
Number of subjects: 17
Study 26041132 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional education (IPE) programme (11 hours)
Number of subjects: 83
Study 26041132 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual discipline specific curriculum)
Number of subjects: 83
Study 23517809 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder-rectum spacer balloon (BRSB)
Number of subjects: 40
Study 23517809 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze packing
Number of subjects: 40
Study 21917518 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based treatment
Number of subjects: 3452
Study 21917518 — intervention group
Group type: COMPARATOR
Intervention: Altered TOP2A cohort (deleted and amplified combined)
Number of subjects: 3452
Study 18937013 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary risk profile every three months
Number of subjects: 2631
Study 18937013 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2631
Study 16913498 — intervention group
Group type: EXPERIMENTAL
Intervention: Dan Shao Tang (DST) and western medicine
Number of subjects: 72
Study 16913498 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 72
Study 15496698 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids treatment in head injury (intervention group where consent was waived)
Number of subjects: 0
Study 15496698 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids treatment in head injury (control group where consent was required)
Number of subjects: 0
Study 11273944 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% bupivacaine/4 microg fentanyl
Number of subjects: 40
Study 11273944 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine/fentanyl
Number of subjects: 40
Study 11273944 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% ropivacaine/fentanyl
Number of subjects: 40
Study 11273944 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine/fentanyl
Number of subjects: 40
Study 11273944 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% or 0.1% solutions of bupivacaine/fentanyl and ropivacaine/fentanyl
Number of subjects: 40
Study 11273944 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% solution
Number of subjects: 40
Study 9563925 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b and ursodeoxycholic acid
Number of subjects: 31
Study 9563925 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha 2b alone (monotherapy)
Number of subjects: 31
Study 9316679 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 158
Study 9316679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 3592847 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oxpentifylline thrice daily for 12 weeks
Number of subjects: 25
Study 3592847 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo tablets for 12 weeks
Number of subjects: 25
Study 3592847 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oxpentifylline for MID patients (n = 4)
Number of subjects: 25
Study 3592847 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for MID patients (n = 7)
Number of subjects: 25
Study 3592847 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oxpentifylline for PDD patients
Number of subjects: 25
Study 30755718 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV inflations associated with patient effort
Number of subjects: 14
Study 30755718 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breaths without ventilator assistance
Number of subjects: 14
Study 30755718 — intervention group
Group type: COMPARATOR
Intervention: Ventilator-only inflations
Number of subjects: 14
Study 29293900 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced Choice Recognition (FCR) ≤15
Number of subjects: 104
Study 29293900 — intervention group
Group type: COMPARATOR
Intervention: Forced Choice Recognition (FCR) ≤14
Number of subjects: 104
Study 29293900 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who failed the FCR
Number of subjects: 104
Study 26564446 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal changes in corneal curvature (CC)
Number of subjects: 469
Study 26564446 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between axial length (AL) and corneal curvature (CC)
Number of subjects: 469
Study 26564446 — intervention group
Group type: EXPERIMENTAL
Intervention: Average axial length/corneal radius (AL/CR) ratio
Number of subjects: 469
Study 24731620 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 40
Study 24731620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22257825 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ plus WBI (30 Gy in 10 fractions over 2 weeks with 200 mg TMZ on M/W/F and 300 mg TMZ on T/Th)
Number of subjects: 55
Study 22257825 — intervention group
Group type: COMPARATOR
Intervention: WBI alone (30 Gy in 10 fractions over 2 weeks)
Number of subjects: 55
Study 22257825 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ plus WBI
Number of subjects: 55
Study 22257825 — intervention group
Group type: COMPARATOR
Intervention: WBI alone
Number of subjects: 55
Study 20680385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice water ingestion (250 ml)
Number of subjects: 53
Study 20680385 — intervention group
Group type: COMPARATOR
Intervention: Room temperature water ingestion (control)
Number of subjects: 53
Study 17714551 — intervention group
Group type: EXPERIMENTAL
Intervention: Alutard SQ P. pratense 100,000 SQ-U
Number of subjects: 410
Study 17714551 — intervention group
Group type: EXPERIMENTAL
Intervention: Alutard SQ P. pratense 10,000 SQ-U
Number of subjects: 410
Study 17714551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 14709940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 16
Study 14709940 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 16
Study 14709940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 16
Study 14709940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 16
Study 11137416 — intervention group
Group type: EXPERIMENTAL
Intervention: neostigmine + bupivacaine
Number of subjects: 30
Study 11137416 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine + bupivacaine
Number of subjects: 30
Study 11137416 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine alone
Number of subjects: 30
Study 9099400 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) - intensive smoking cessation program
Number of subjects: 12866
Study 9099400 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12866
Study 9099400 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 12866
Study 9099400 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) and Usual Care (UC)
Number of subjects: 12866
Study 8265878 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (20 mg daily for 14 days)
Number of subjects: 16
Study 8265878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3011023 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (6.6 g)
Number of subjects: 16
Study 3011023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no guar gum)
Number of subjects: 16
Study 2890550 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine sodium 0.75 g
Number of subjects: 66
Study 2890550 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine sodium 1.5 g
Number of subjects: 66
Study 2890550 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine sodium 3 g
Number of subjects: 66
Study 2890550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined olsalazine group
Number of subjects: 66
Study 2890550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 2890550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopic criteria
Number of subjects: 66
Study 30537261 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T (TnT) elevated to >18 ng/L and NT-proBNP in the highest tertile (9% of all patients)
Number of subjects: 1907
Study 30537261 — intervention group
Group type: COMPARATOR
Intervention: Troponin T (TnT) <18 ng/L and NT-proBNP in the lowest tertile (16% of all patients)
Number of subjects: 1907
Study 28535776 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE)
Number of subjects: 0
Study 28535776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25592014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 63
Study 25592014 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 63
Study 25592014 — intervention group
Group type: COMPARATOR
Intervention: Semi-vegetarian diet
Number of subjects: 63
Study 25592014 — intervention group
Group type: COMPARATOR
Intervention: Pesco-vegetarian diet
Number of subjects: 63
Study 22458649 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention (4 days/week of exercise for 45 min/day and 1 day/week of nutritional counselling for 6 months)
Number of subjects: 221
Study 22458649 — intervention group
Group type: COMPARATOR
Intervention: Self-help control
Number of subjects: 221
Study 21455612 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT + fortified milk supplement
Number of subjects: 180
Study 21455612 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk supplement
Number of subjects: 180
Study 21455612 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT
Number of subjects: 180
Study 21455612 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 17611123 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-involvement through guided evaluative processing and explicit association with self
Number of subjects: 0
Study 17611123 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection (choice-based processing)
Number of subjects: 0
Study 16426962 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified beverage
Number of subjects: 869
Study 16426962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 869
Study 15330403 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial service utilization (therapy with a psychologist, self-help group, therapy with a social worker, therapy with another type of provider)
Number of subjects: 500
Study 15330403 — intervention group
Group type: COMPARATOR
Intervention: Presence of personality disorders
Number of subjects: 500
Study 15330403 — intervention group
Group type: COMPARATOR
Intervention: Presence of alcohol/drug abuse disorders
Number of subjects: 500
Study 15330403 — intervention group
Group type: COMPARATOR
Intervention: Presence of anxiety disorders
Number of subjects: 500
Study 15330403 — intervention group
Group type: COMPARATOR
Intervention: Global functioning
Number of subjects: 500
Study 15330403 — intervention group
Group type: COMPARATOR
Intervention: Marital status
Number of subjects: 500
Study 11130743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 200 mg
Number of subjects: 8
Study 11130743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9228814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ineraid cochlear implant with analog processing
Number of subjects: 49
Study 9228814 — intervention group
Group type: COMPARATOR
Intervention: Nucleus cochlear implant with feature-extraction processing
Number of subjects: 49
Study 9228814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Ineraid and Nucleus cochlear implants
Number of subjects: 49
Study 8112068 — intervention group
Group type: EXPERIMENTAL
Intervention: Locobase (moisturizer) used for 2 weeks (period L)
Number of subjects: 111
Study 8112068 — intervention group
Group type: COMPARATOR
Intervention: No treatment (period C)
Number of subjects: 111
Study 3527853 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-side portacaval shunt (PCS)
Number of subjects: 54
Study 3527853 — intervention group
Group type: COMPARATOR
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 54
Study 29979913 — intervention group
Group type: EXPERIMENTAL
Intervention: Why-Quit messages
Number of subjects: 0
Study 29979913 — intervention group
Group type: EXPERIMENTAL
Intervention: How-To-Quit messages
Number of subjects: 0
Study 26710753 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Brush with chlorhexidine 0.12%
Number of subjects: 56
Study 26710753 — intervention group
Group type: COMPARATOR
Intervention: Sterile gauze soaked in water (Control)
Number of subjects: 56
Study 24456049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Number of subjects: 356
Study 24456049 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 356
Study 23913601 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective infarct-related artery (sIRA) infusion of tirofiban (10 g/kg body weight) through aspiration catheter followed by 12 hours of intravenous infusion (0.1 g/kg/min)
Number of subjects: 203
Study 23913601 — intervention group
Group type: COMPARATOR
Intervention: Conventional intracoronary (IC) administration of tirofiban (10 g/kg body weight) through guiding catheter followed by 12 hours of intravenous infusion (0.1 g/kg/min)
Number of subjects: 203
Study 23913601 — intervention group
Group type: EXPERIMENTAL
Intervention: sIRA infusion of tirofiban
Number of subjects: 203
Study 23913601 — intervention group
Group type: COMPARATOR
Intervention: Conventional IC administration of tirofiban
Number of subjects: 203
Study 20159127 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up & Go (TUG)
Number of subjects: 237
Study 20159127 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAF-mobility
Number of subjects: 237
Study 20159127 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAF-ADL
Number of subjects: 237
Study 20159127 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAF-IADL
Number of subjects: 237
Study 18436152 — intervention group
Group type: EXPERIMENTAL
Intervention: IV/IA (0.6 mg/kg IV ≤ 60 mg, followed by 0.3 mg/kg IA ≤ 30 mg)
Number of subjects: 1057
Study 18436152 — intervention group
Group type: COMPARATOR
Intervention: IA therapy
Number of subjects: 1057
Study 18436152 — intervention group
Group type: EXPERIMENTAL
Intervention: IV/IA
Number of subjects: 1057
Study 16401336 — intervention group
Group type: EXPERIMENTAL
Intervention: FITT framework applied to nursing documentation system adoption
Number of subjects: 0
Study 14714839 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular conventional dentures
Number of subjects: 58
Study 14714839 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported overdentures
Number of subjects: 58
Study 10697342 — intervention group
Group type: EXPERIMENTAL
Intervention: Buckley's Formocresol (F)
Number of subjects: 52
Study 10697342 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide (C)
Number of subjects: 52
Study 8713772 — intervention group
Group type: EXPERIMENTAL
Intervention: VIDAS D‐dimer ELISA, cut-off level of 500 ng/ml
Number of subjects: 195
Study 1439288 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 23
Study 1439288 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 23
Study 2986932 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate
Number of subjects: 30
Study 2986932 — intervention group
Group type: COMPARATOR
Intervention: methohexital
Number of subjects: 30
Study 2986932 — intervention group
Group type: COMPARATOR
Intervention: midazolam
Number of subjects: 30
Study 30206824 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.25% finasteride combined with topical 3% minoxidil
Number of subjects: 30
Study 30206824 — intervention group
Group type: COMPARATOR
Intervention: Topical 3% minoxidil solution as monotherapy
Number of subjects: 30
Study 30371169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 weeks
Number of subjects: 119
Study 30371169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training with lipopolysaccharide 0.1 ng/mL
Number of subjects: 119
Study 30371169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training with lipopolysaccharide 1.0 ng/mL
Number of subjects: 119
Study 30371169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 119
Study 30371169 — intervention group
Group type: COMPARATOR
Intervention: Wait list control condition
Number of subjects: 119
Study 27423256 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-063 (PDE10A inhibitor)
Number of subjects: 12
Study 27423256 — intervention group
Group type: COMPARATOR
Intervention: Baseline PET
Number of subjects: 12
Study 25483462 — intervention group
Group type: EXPERIMENTAL
Intervention: GC FLU Prefilled Syringe
Number of subjects: 1023
Study 25483462 — intervention group
Group type: EXPERIMENTAL
Intervention: GC FLU Injection
Number of subjects: 1023
Study 22218277 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second video with qualitative description
Number of subjects: 409
Study 22218277 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second video with relative risk
Number of subjects: 409
Study 22218277 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second video with absolute risk
Number of subjects: 409
Study 22218277 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second video with absolute event-free survival
Number of subjects: 409
Study 22218277 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second video with annualized absolute risk
Number of subjects: 409
Study 19629583 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhanced diet (ID) group, n = 30
Number of subjects: 60
Study 19629583 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet (CD) group, n = 30
Number of subjects: 60
Study 17613965 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-hydroxybutyrate (GHB) 50 mg/kg bodyweight, q.i.d.
Number of subjects: 42
Study 17613965 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.5 mg/kg bodyweight, q.i.d.
Number of subjects: 42
Study 15002017 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2%
Number of subjects: 25
Study 15002017 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 25
Study 15002017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11355117 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin plus piperacillin/tazobactam (n = 88)
Number of subjects: 124
Study 11355117 — intervention group
Group type: COMPARATOR
Intervention: Amikacin plus ceftazidime (n = 36)
Number of subjects: 124
Study 11355117 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin plus piperacillin/tazobactam
Number of subjects: 124
Study 11355117 — intervention group
Group type: COMPARATOR
Intervention: Amikacin plus ceftazidime
Number of subjects: 124
Study 9554427 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (imaginal and live)
Number of subjects: 87
Study 9554427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring alone
Number of subjects: 87
Study 9554427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined prolonged exposure and cognitive restructuring
Number of subjects: 87
Study 9554427 — intervention group
Group type: COMPARATOR
Intervention: Relaxation without prolonged exposure or cognitive restructuring
Number of subjects: 87
Study 8111604 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol hydrochloride (10 micrograms/puff, 2 puffs)
Number of subjects: 8
Study 8111604 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (20 micrograms/puff, 2 puffs)
Number of subjects: 8
Study 8111604 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol hydrochloride
Number of subjects: 8
Study 8111604 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide
Number of subjects: 8
Study 3182457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 100 mg bd
Number of subjects: 61
Study 3182457 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg bd
Number of subjects: 61
Study 3182457 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 61
Study 3182457 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 61
Study 31194645 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct distribution system (cross-docking arrangement)
Number of subjects: 439